EBRD finances expansion of pharma company Jadran Galenski Laboratorij

RELATED ARTICLES

Romanian logistics park receives European funding for expansion

EBRD and EU jointly helping SMEs in Bosnia and Herzegovina

A waste-oil recycling project to be implemented in Romani

Kosovan pharmaceutical company gets EBRD funding to build a greenfield logistics centre

Serbia begins work on its largest wind farm project

JGL opened its new eco-friendly facility Pharma Valley

Latest SEE projects

The European Bank for Reconstruction and Development (EBRD) is supporting the expansion of Jadran Galenski Laboratorij d.d. (JGL) with a 20 million euro multi-currency loan. The Croatian pharmaceutical company aims to become a world leader in the sterile solutions segment.

The EBRD financing will allow the company to double its production capacities. Founded in 1991, Jadran Galenski Laboratorij is the second largest pharmaceutical company in Croatia specializing in the production of sterile nose, eye and ear drop solutions. The company exports 75 per cent of its production.

To meet rising demand, JGL is expanding its production facilities with the construction of a new ”Pharma Valley”, which will double its output in sterile solutions and create 100 new jobs. The EBRD’s loan will be complemented by a 32.7 million euro loan provided by the Croatian Development Bank HBOR.

Vedrana Jelusic Kasic, EBRD Director for Croatia, said: ”We are very proud to support a strong private Croatian company to become even stronger. Jadran Galenski Laboratorij serves as an example of the country’s potential in terms of entrepreneurship, innovation and know-how. We hope that many more local companies will emulate this successful example.”

Ivo Usmiani, President of the Jadran Galenski Laboratorij Management Board, said: ”We are very pleased that a reputable financial institution such as the EBRD has recognized JGL as a long-term partner. The loan will finance working capital needed for our ongoing investment projects while providing additional support to our strong growth and sustainable development.

This will ensure the capacities for research and development, production and storage and will support JGL in taking a further strategic step in selected therapeutic areas in the global pharmaceutical market.”

The EBRD has been active in Croatia as an investor since the country’s independence and has invested more than 3.08 billion euro in over 170 projects to date. The Bank’s activities include all areas of the economy and are especially strong in the infrastructure, corporate, financial institutions and energy sectors.